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Understanding Dose Intensity is Essential
for Optimizing Chemotherapeutic Regimens
by Stephen L. Huber, M.S.
Director) Pharmacy Patient Care Services
Nicky Dozier, Pharm.D.
Assistant Director) Pharmacy Patient Care Services/Clinical

Stephen L. Huber

greater safety and activity against resistant clones, and clinical improvements in supportive care. It now seems likely
that the concept of dose intensity-will emerge as an important new paradigm for optimizing chemotherapeutic
regimens.
The therapeutic implications of dose intensity are significant for practicing oncologists, oncology pharmacists, and
other health-care personnel who administer chemotherapy.
Oncologists who understand the potential applications of
dose intensity, as well as its limitations, will be able to
integrate the concept into individual patient treatment
programs.

Nicky Dozier

Recent advances in the treatment of antineoplastic disorders have placed clinical cures within reach. As information
has accumulated on antineoplastic pharmacology, immunology, tumor biology, cytokinetics, and drug resistance,
therapeutic strategies have been developed to maximize
tumor cell kill and to overcome or minimize resistance,
enhancing the potential for cure by chemotherapy. An
important component of many emerging strategies is dose
intensity, a concept that stresses that the amount of drug
delivered per unit time is a major determinant of outcome.
Dose intensity acknowledges 1) the clonal nature of tumor
growth and thus the need to eradicate every viable tumor
stem cell, 2) the heterogeneity within tumors of cell sensitivity to chemotherapy, and 3) the existence of essential
dose-response relationships in chemotherapeutics.
Three major advances are moving dose intensity into the
clinical arena: specialized dosage forms for more targeted
drug delivery, synthetic chemotherapy analogues that have

Dose Intensity
Dose intensity is the amount of drug delivered per unit
time, expressed as mg/m 2 /week (regardless of schedule).
Emphasis is placed on the time over which chemotherapy is
administered.
Ardent supporters of the dose intensity concept beEeve
that the most important adverse effect of treatment may be
death from insufficient treatment or from a lack of dose
continued on page 2

ONcoLoa ·
intensity. Certainly, one of the most common problems
with chemotherapy is toxicity; however, concern over toxicity may at times be out of proportion to the fatal consequences of the disease itself. For example, after the original
National Cancer Institute MOPP (mechlorethamine,
Oncovin (vincristine), procarbazine, prednisone) protocol
for Hodgkin's disease was modified to reduce treatmentinduced toxicity, dose intensity decreased 29-38%. However, overall disease-free survival also decreased by 33-35%.
'Iranslated to a national forecast, the decreased dose intensity could result in the overall loss oflives ofl 000 patients
per year, a "side effect" that far exceeds the treatmentinduced mortality from full doses of MOPP chemotherapy.

Supportive Care Techniques Reduce Toxicity
Designing safe regimens that maximize dose intensity
should be facilitated by the recent strides in supportive
care. Techniques that reduce the risks of chemotherapyinduced toxicity are critical to the effective management of
many cancers. Supportive measures such as protected environments, broad-spectrum antibiotics, analgesics, and
blood products have decreased the risks associated with
high-dose chemotherapy and enabled patien ts to tolerate
more dose-intense therapies. The new drugs and biological
products available to reduce the morbidity associated with
chemotherapy-induced myelosuppression include potent
antibiotics (such as ceftriaxone, ciprofloxacin, and imipenem), blood products, intravenous immunoglobulins,
and hematopoietic growth factors. The hematopoietic
growth factors are undergoing rigorous clinical evaluation
in myelosuppressed patients, since they stimulate the production of macrophages, granulocytes, or both . The hope
is that these compounds may eventually eliminate myelosuppression as a dose-limiting side effect of chemotherapy.
Improved antiemetic combinations also favor the use of
higher doses in individual patient regimens. Serotonin
antagonists, now under investigation, will soon be added
to the armamentarium of effective antinauseants for chemotherapy. Effective antiemetic therapy for regimens containing anthracycline, cisplatin, or dacarbazine are necessary so that patients can tolerate full therapeutic doses of
these agents.

Skeptics of dose intensity emphasize that the concept
neglects important host variables such as drug disposition,
tumor burden, and tumor stage. Moreover, the lack of a
demonstrable dose-response curve for some drugs calls into
question the necessity of dose intensity in certain situations. Clearly much research remains to be done; nevertheless, dose intensity is finding a niche in the clinic, especially
in the treatment oflymphomas, breast cancer, ovarian cancer, small cell lung cancer, and advanced colorectal cancer.
In these diseases, better response rates have been correlated
retrospectively with increased dose intensity.
Clinical trials have demonstrated important correlations
~ ~-w~n-d-Gse intensitY-4n.d-r--espons~m:. .{;-i.splati-1-H ·-H--- -- - - - - -- - -- - - - - -- -- - - - - -- ~ -ovarian cancer, doxorubicin and cisplatin in endometrial
cancer, 5-fluorouracil (5-FU) in advanced colorectal canSynthetic Analogues Offer Greater Potential Safety
cer, and multiagent combinations for Hodgkin's disease,
and Efficacy.
breast cancer, and small cell lun~ cancer. Ongoing clinical
Advances in drug development have made possible the
trials designed to validate these findings prospectively and
synthesis of analogues of some of the more active chemoto evaluate the importance of dose intensity in other contherapeutic agents. These agents offer potential advantages
ventional chemotherapeutic regimens should further delinover the parent compounds in terms of safety and efficacy
eate the diagnoses and treatment regimens for which dose
against resistant cell lines. Two such com pounds are carbointensity is essential to therapeutic outcome. Moreover, as
platin and mitoxantrone. These drugs, which have become
the concept is incorporated into the design and reporting
commercially available in recent months, are synthetic anaof clinical trials, interstudy comparisons of data and results
logues of cisplatin and doxorubicin, respectively. The
enhanced anti tumor activity of these and other analogues
may be improved.
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in clinical trials, coupled with improved safety profiles that
allow increased dose intensity, might translate into greater
disease-free survival for certain patient populations .

being evaluated for doxorubicin, methotrexate, and
melphalan.
New approaches to treatment are being investigated
based on d.ose intensity principles. "Front-end-loading"
regimens call for dose-intense drug therapies in early stages
of disease to de bulk effectively the tumors and inhibit the
emergence of resistance. "Leap frog" sequencing regimens
capitalize on the benefits of dose intensity. Higher doses
are better able to reduce bulk disease and suppress resistant
clones. The most active drugs against the tumor are initially given at high dose intensity to reduce the bulk of the
sensitive tumor mass. During this phase in the sequence,
drugs most active against the likely resistant clones are
given at a lower dose intensity to hold resistant clones in
check. After debulking the tumor, the agents active in
bulk disease may be deleted or decreased so that dose intensity may be increased for the drugs most active against the
resistant mutants. Chemotherapy administered in such a
sequencing fashion may improve overall cell kill and potential for cure.

Specialized Dosage Forms Enhance Antitumor
Activity
Recent technologic developments have made possible
sophisticated drug delivery devices, genetically engineered
compounds, liposomal drug-carrier systems, and monoclonal antibodies (MoAbs) to enhance targeted drug delivery, thereby improving the therapeutic index of drug
treatments. These new formulations currently are being
investigated as tools to increase achievable dose intensity
while minimizing systemic toxicity. ·

Regional drug delivery by intraarterial administration of
chemotherapy improves the therapeutic index by providing
high drug concentrations to cancerous tissue while minimizing the systemic drug delivery. Advanced by improvements in vascular access devices and in implantable or programmable infusion pumps, the technique offers another
means of maintaining dose intensity. Results with floxuridine (FUDR) administered intrahepatically via an implantable infusion pump to patients with metastatic liver disease
have been favorable. Future applications are promising.
Other targeted drug delivery options are being investigated to maximize dose intensity at the tumor site. Chemoembolization uses drug-loaded microspheres to create a
" chemotherapy bullet" capable of delivering high concentrations of drug to highly vascular tumors. Liposomes are
phospholipid vesicles with aqueous compartments that
entrap drugs and serve as drug carriers. Liposomal carriers
are being evaluated to improve the therapeutic efficacy and
dose intensity of anticancer drugs (cisplatin, carboplatin,
doxorubicin), antifungals (amphotericin-B), and other
pharmacologic agents.
MoAbs represent another approach for achieving cytotoxic specificity. Conjugates of MoAbs with chemotherapeutic agents, plant toxins, biologicals, and radioisotopes
are under investigation for both diagnostic and therapeutic
uses. Immunoconjugates that deliver drugs directly to the
tumor site while limiting the exposure of normal cells are

Biochemical modulation using combinations of drugs
enhances overall antitumor activity. Folinic acid combined
with 5-FU enhances 5-FU's activity by providing an excess
of intracellular reduced folates, which increases the inhibition of thymidylate synthetase. This modulatory action
increases the cytotoxic potential of 5-FU in advanced colorectal cancer.
lieatment programs that optimize dose intensity are
finding their way to the oncology clinic. The use of supportive therapies such as parenteral antibiotics, nutritional
support, blood products, and hematopoietic growth
factors are becoming standard components of oncology
practice in both inpatient and outpatient settings. The
challenge before oncologists facing patient care decisions
will be to balance risk and benefit in a reasonably costefficient manner. ■
Physicians who desire additional information may write Stephen L.
Huber, M.S. , or Nicky Dozier, Pharm.D ., Division of Pharmacy,
Box 90 , The Uni versity of Texas M . D . Anderson Cancer Center,
1515 Holcombe Boulevard , Houston , Texas 77030 , or call
(713) 792-2870.
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Multiple Endocrine Neoplasia Syndromes
parathyroid-stimulating hormone, but the origin of this
factor has yet to be established. We found that the ideal
approach for treating this particular condition is to remove
the four parathyroid glands and transplant half of one gland
in the forearm to allow monitoring of serum parathyroid
hormone and calcium levels. It is also possible to remove
three and a half parathyroid glands , leaving half a gland in
the neck, marked by a silver clip to aid in x-ray localization.
If hypercalcemia recurs, the parathyroid tissue can be
removed and transplanted in the forearm. This form of
autotransplantation was developed by Robert C. Hickey,
M.D., at M. D. Anderson and by Sam Wells, M .D., at
Duke University in independent and simultaneous studies.

by Naguib A. Samaan, M.D., Ph.D., F.A.C.P., F.R.C.P.
Chief; Section ofEndocrinology
Professor ofMedicine

The multiple endocrine neoplasia (MEN) syndrome has
become one of the most interesting subjects in medicine and
surgery over the last two decades. MEN consists of various
subtypes whose treatment
requires various strategies and
the combined efforts of memNaguib A. Samaan
bers from practically all disciplines of medicine .
MEN I is a highly penetrant autosomal-dominant disease
involving the pituitary gland, parathyroid gland, and pancreas. MEN II-a carcinoma of the medullary thyroid-is
also genetically based and may appear with or without parathyroid adenoma or hyperplasia and bilateral pheochromocytoma. Such cases are termed MEN IIA. MEN IIB is
identical to IIA, except that mucosa! neuromata-possibly
involving the gastrointestinal tract from the mouth to
the anal opening-are also present. MEN IIB may also be
associated with musculoskeletal deformities or marfanoid
habitus. MEN IIB has also been termed MEN III.

Autotransplantation is Ideal for MEN I
Parathyroid Hyperplasia

MEN I Pancreatic Tumors Were Found
to be Multiple

Most patients with MEN I are referred to us for management of hypercalcemia, which often suggests parathyroid
hyperactivity or the presence of a pancreatic tumor, with
symptoms suggesting the presence of a functioning islet cell
tumor. This kind of tumor may produce insulin, resulting
in hypoglycemia; glucagon, resulting in diabetes with or
without skin ulcerations; gastrin, resulting in gastric ulcers;
or vasoactive intestinal peptide, causing severe diarrhea and
hypokalemia . Patients may also be referred because of
amenorrhea with or without galactorrhea. Although the
presenting symptoms are usually related to only one
tumor, careful examination usually reveals pituitary or
parathyroid tumors, as well as pancreatic tumor.
In our studies at the M. D. Anderson Cancer Center, we
have studied five families with MEN I syndrome. In one of
these families alone, 9 of245 members identified so far had
the disease. In this syndrome, 95% of patients havehypercalcemia that is due to hyperplasia of the parathyroid glands. Steve Marks, M.D., and Gerald Orebach, M .D., of
the National Institutes of Health have found some experimental evidence that this hyperplasia is most likely due to

We have identified and examined 20 patients from the
five families with MEN I syndrome. Fourteen had hormoneproducing pancreatic tumor, such as gastrinoma, insulinoma, glucagonoma, vipoma, or polypeptide-producing
tumor. Multiple pancreatic tumors usually occurred
throughout the pancreas. We found that the pancreatic
tumor may secrete several hormones , but one was usually
predominant and caused the clinical symptoms . The treatment of choice generally was total pancreatectomy,
especially in patients with gastrinoma, since t he tumor is
found in diffuse forms throughout the pancreas . Subtotal
pancreatectomy in patients with insulinoma has been successful, with no recurrence up to 12 years . Long-term
follow-up is needed to determine the ideal approach.
Pancreatic tumors have the potential of metastasizing to
the liver, in which case the treatment of choice is liver
embolization. Chemotherapy in the form of 5-fluorouracil,
streptozotocin, and doxorubicin has been shown to be
effective in 20 to 30% of patients. Also effective is a
somatostatin analogue, SMS 201-995 (Sandoz Drug Co.),
which palliates the symptoms caused by an excess of the
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gastrointestinal peptide; however, this drug may not
inhibit tumor growth . I nterferon is currently being
investigated.
Anterior pituitary tumors were seen in 40% of patients
with MEN I syndrome. Of these, 85% were prolactinproducing tumors , and 15% were growth hormoneproducing tumors (acromegaly). Women had amenorrhea,
which was sometimes accompanied by galactorrhea and
infertility, whereas men were impotent and sterile. We
found that the best treatment for prolactinoma was the
administration of the dopamine agonist bromocriptine.
With this drug, tumor size decreases, the serum prolactin
level returns to normal, and the pituitary gland may reach
normal size. Women will regain their menses and fertility,
and men will regain their potency and fertility. Bromocriptine, taken by m ou th , may initially cause slight nausea,
headache, and blurred vision, but these symptoms usually
disappear with continued treatment. Recently, an experimental drug called CV 205-502 (Sandoz) has been used in
a limited number of centers. This drug is also a dopamine
agonist but, unlike bromocriptine, is not an ergot alkaloid
derivative. We administered CV 205-502 to 15 patients
with prolactinoma. In all patients serum levels returned to
normal and tumor size decreased. No patient complained
of the side effects we have seen with bromocriptine.

mone level, and adrenocortical-stimulating hormone level.

Calcitonin Measurements Detect MEN II
MEN II, or medullary thyroid carcinoma, is a tumor of
the C-cells (parafollicular cells), which secrete calcitonin.
MEN II may occur in the sporadic or familial form. Like
MEN I, the familial form of MEN II is a highly penetrant
autosomal-dominant trait. The patient's prognosis is best
when disease is localized in the thyroid gland. The disease
should be treated by total thyroidectomy, and the lymph
nodes in the neck should be sampled. If they are involved,
a modified bilateral neck dissection should be performed.
If there is muscle involvement, a radical neck dissection
with removal of these muscles should be done. Radiotherapy in these cases may be considered, especially if the surgeon has a high degree of suspicion of residual disease. However, medullary carcinoma is resistant to radiotherapy, and
iodine-131 therapy has not proved effective; in fact, no
effective chemotherapy has yet been established for distant
metastases.

Over the last 20 years, M. D. Anderson has treated 225
patients with MEN II, which constitutes the largest number of patients diagnosed at one institution. Measurement
of calcitonin at basal or after pentagastrin stimulation is the
best method of detecting MEN II. We were among those
who established the radioimmunoassay of calcitonin. We
also showed that serum calcitonin is high in the normal
fetus and the normal pregnant mother. The high calcitonin
in the fetus appears to be important in fetal bone formation. In pregnant mothers, it appears to prevent bone loss
during pregnancy by inhibiting bone resorption induced
by the high parathyroid hormone present during pregnancy. We also found that serum calcitonin, which is high
during early life, progressively decreases with age and
reaches the normal adult level between ages 7 and 10 years.
In children of family members with MEN II, however, we
found that the serum calcitonin level increases with age.
Recently, we diagnosed MEN II in a 3-month-old child.

In patients with acromegaly, we found that transsphenoidal surgery is the best treatment. SMS 201-995, an
octreotide acetate, was recently found to be successful in
the treatment of this disorder, but its long-term effectiveness remains to be proved.
Generally, family members of MEN patients should be
scre.e ned routineiy. We currently know that the MEN syndrome gene maps to chromosome 11, though its exact location remains to be identified. This may shed more light on
the genetic aspects of this disease and possibly result in
genetically based screening techniques. Until genetic techniques become available, clinical screening should be performed for all family members of patients diagnosed with
MEN I. In addition to a careful history and physical examination, a number of routine assays should be performed:
serum calcium and phosphorous levels, basal levels of pancreatic hormones, basal serum prolactin level, growth hor-

continued on page 7
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Dysplastic Nevi continued from page 8
dysplastic are malignant melanomas upon pathological
examination. To some degree, differentiating dysplastic
nevi from malignant melanoma is subjective and depends
on the experience of the pathologist. ''
Dysplastic nevus syndrome, also known as atypical mole
syndrome, was originally described in two families with
familial melanoma. This syndrome can also be sporadic.
Individuals with the sporadic condition, type A, have no
family history of either the syndrome or melanoma. The
familial condition consists of several types. A patient who
has dysplastic nevus syndrome and a family history of t he
syndrome is designated as having type B. In type C, in
addition to the syndrome, the patient has a personal history of melanoma but a family history of neither the syndrome nor melanoma. Type D consists of two forms: type
D 1 patients have one family member with the syndrome
and melanoma, whereas D2 patients have two or more relatives with the syndrome and melanoma. It is estimated that
dysplastic nevi may be found in 30 to 50% of sporadic ,
nonfamilial melanoma patients.

of black may be present, which may indicate malignant
transformation. The borders, unlike those of common
nevi, are ill defined and tend to merge into the surrounding
skin. About 90% of dysplastic nevi occur in the trunk, but
they also can appear in sun-protected areas such as the
female breast, the scalp, or the buttocks. The latter three
areas are diagnostically important, since common acquired
nevi are less common in these locations. For the most part,
dysplastic nevi proper appear only after puberty, though
rudimentary nevi have been identified in individuals as
young as 5 years old. If the syndrome has not developed by
age 25, it likely will not do so.

"Our screening process is quite simple," Duvic said.
"We perform a complete examination of the skin, scalp,
and the mouth. It is also important to examine the eyes,
since ocular nevi and melanoma are a possibility. We pay
attention to any moles in which the dimensions, pigment,
or border has c.:hanged. Symptoms like bleeding or burning
could be a sign that the mole is in the process of transformation. When a patient is initially diagnosed with dysplastic nevus syndrome, we generally encourage other family
members to be examined because of the genetic basis of
this disorder. There is usually someone else in the family
who has had melanoma, which may help confirm the
diagnosis.''
_ _ _ _ _ _ __

_ __ _ _ _ _ __ __ _ _ _ _ __

Dysplastic nevus found on a 15-year-old white male. Note irregular borders that fade into
surrounding skin . Photograph courtesy of Steve Eyre, M.D., The University of Texas
Medical School.

Each of these types carries an increasing risk of developing melanoma. "Sporadic dysplastic nevus syndrome (type
_ __

____.__......),_.,_,_..J.wJ...Jbu...i......
c"'- 'h. __,_o..,_.c__._c.__LJ11u.._r. ,_s

n.,__._,5'---Lr o 10% of the genera I papu larian,

_.L.li

raises your chances of developing melanoma by five- to
sevenfold, even if you have just one dysplastic nevus ,''
Duvic said.
The most dramatic increase in risk, however, is familial
dysplastic nevus syndrome. Risk ranges from 148-fold
greater for families in which type B dysplastic nevus syndrome has been identified to 500-fold in families identified
with type D2. The latter was initially termed B-K syndrome by Mark H. Greene, M.D., and coworkers of the
National Cancer Institute. (The initials were derived from
two of the seven families studied.) These investigators
noted a relationship between dysplastic nevi and the subse-

Diagnosis Must Be Confirmed Pathologically
As yet, there are no absolute clinical criteria that can be
used for a definitive diagnosis of dysplastic nevi. Macroscopically, such nevi can resemble malignant melanoma.
On the microscopic level, dysplastic nevi are characterized
by variably atypical melanocytes, a lentiginous epidermal
pattern, fibrosis of the upper dermis, and a nevocytic component. Nevertheless, these qualities are not always sufficient for a definitive diagnosis. "That's why it's essential for
an experienced dermatopathologist to confirm any clinical
diagnosis," Duvic said. "Sometimes lesions that appear
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quent development of melanoma. Virtually all family
members with a personal history of melanoma had dysplastic nevi, and of the 39 new melanomas that developed during the study, all occurred in patients who had dysplastic
nevus syndrome. In stark contrast, of the patients who had
normal skin, none developed melanoma during the course
of the study. From a prevention and treatment standpoint,
however, the most important finding was that the new
melanomas were detected at an early, highly curable stage in
their development. Thirty-six were less than O. 7 6 mm in
diameter. Patients who have lesions of this size have virtually a 100% cure rate. Consequently, identifying dysplastic
nevi is the first step in identifying patients at high risk for
melanoma.
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MEN Syndromes continued from page 5

Some Aspects of Treatment are Controversial
There is no disagreement as to treatment for an individual
dysplastic nevus that may be on the pathway to malignancy: local excision. However, patients with the syndrome can have more than 100 moles. Whether to excise
all of them or only those that are suspicious is currently a
subject of controversy, according to Du vie. "There are
about as many different opinions as there are dermatologists and pathologists," Duvic said. "And I don't think
that the truth is known yet. Removing every mole is probably unrealistic because of the amount of surgery involved
and the fact that these individuals continually develop new
moles. What is realistic, however, is following the nevi. If
any change occurs in size, color, or shape, then local excision is called for. At M. D. Anderson we make this decision
on an individual basis. Changing or suspicious moles are
excised and examined microscopically. In the future, linkage of familial melanoma and dysplastic nevi to certain
genes may become a possibility." ■

The disease was suspected soon after birth. On clinical
examination, the infant had skeletal deformities and neuromata of the gut. The diagnosis was confirmed by calcitonin
measurement of the peripheral blood, which showed a rise
(rather than a fall) after 3 months. The patient underwent
a thyroidectomy, which revealed the calcitonin-cell
hyperplasia before tumor formation. We expect no recurrence of thyroid disease. Even though calcitonin is the
most useful diagnostic marker, carincoembryonic antigen
(CEA) is a better prognostic marker. We have found that
patients with a progressive increase of CEA levels have
poor prognosis.
We also found that in familial MEN II with bilateral
pheochromocytoma, bilateral adrenalectomy with partial
preservation of the normal adrenal cortex is the treatment
of choice since the patient will not be dependent on steroid
hormone replacement. ■

Physicians who desire additional information may write Naguib A.
Samaan, M.D., Ph.D., F.A.C.P., F.R.C.P., Department of Medical
Specialties, Box 65 , The University of Texas M . D. Anderson Cancer
Center, 1515 Holcombe Boulevard, Houston, Texas 77030, or call
(713) 792-2840.

Physicians who desire additional information may write Madeleine
Duvic, M.D., Department of Dermatology, Box 47, The University of
Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, Texas 77030, or call (713) 792-2490.
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Dysplastic Nevus Syndrome Identifies Patients
at High Risk for Melanoma
change but d pla tic ne i are particular! important
d spla ti n u
ndrome an
becau e of the a sociated ri k of melanoma. ormal mole
pla a critical r le in curing
t nd to be mall brown and uniform! colored wherea
melanoma. Mounting id nee
d pla ti ne i are large and their pigm ntation i ariesuggests that d pla tic ne,i ar
gat d. Recent! Alfred W. Kopf M .D. and colleagues at
the histogenic precur or of
e York Uni er it defined three clinical criteria indicamalignant melanoma. E en if
ti e of the d spla tic n vu
ndrom : the pre nee of 100
nicular----dysplastic----ne-vus>-- - - -H-mtt-Ornle=-or-m~Gl gi-e-atei:-t-h.an--8--mm-Ul-diam.eter.,--and_ --l
does not itself become maligmoles wi th irregular border and ariegated pigment. '
I
Madeleine Duvic
nant, the patient still has a 7D spla tic ne i represent an intermediate stage b tween
to 70-fold increased risk of
common acquired nevi and malignant melanoma. Common
I
developing melanoma in some other area of the body.
acquired ne i de elop along a predictable path beginning
" Since melanoma is curable if caught early, the bottom
as 1- to 2-mm macules. As the nevus approaches 6 mm
line is that any suspicious lesion should be removed ," said
lateral growth ceases and cells penetrate the under! ing
Madeleine Duvic, M.D., the chief of Dermatology Section
dermis. As the nevus continues to descend the epidermal
at the M. D. Anderson Cancer Center.
appearance becomes clinically normal. D splastic ne i
For this reason, Duvic and coworkers in the Dermatology
however, deviate from this pattern of de elopment. These
Clinic pay particular attention to dysplastic nevi. "We follesions range from 5 to 12 mm and usuall are shades of
low patients on a regular basis-every 6 to 12 months, '
dark brown, brown tan or pink. In some cases focal areas
Du vie said. "Generally, we monitor all moles for any
continued on page 6
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